R
Recursion Pharmaceuticals, Inc. (RXRX)
NMS – Real Time Price. Currency in USD
2.94
-0.21 (-6.67%)
At close: Mar 27, 2026, 4:00 PM EDT
2.96
+0.02 (0.68%)
After-hours: Mar 27, 2026, 7:59 PM EDT

NMS – Real Time Price. Currency in USD
2.94
-0.21 (-6.67%)
At close: Mar 27, 2026, 4:00 PM EDT
2.96
+0.02 (0.68%)
After-hours: Mar 27, 2026, 7:59 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 5.50 | 6.05 | 10 | |
| Quick ratio | 5.50 | 5.63 | 10 | |
| Debt to Equity | 0.07 | 0.30 | 9.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 40M | 45M | 59M | 75M | 75M |
| Gross Profit | -9M | -7M | -5M | -46M | -46M |
| Operating Income | -246M | -350M | -479M | -648M | -648M |
| Net Income | -239M | -328M | -464M | -645M | -645M |
| EBITDA | -226M | -318M | -443M | -564M | -564M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 17.83 | 50 | 9.5 |
| Next quarter | -8.62 | 41.46 | 5.5 |
| Current year | 14.87 | 34.26 | 9.0 |
| Next year | 66.49 | 10.11 | 8.5 |
| Weighted average score | 8.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 586.72 | 33.36 | 41.67 | 59.77 | 10 |
| Y/Y | 681.74 | 39.56 | 60.38 | 59.46 | 10 |
| 3y average | 23.6 | -39.11 | -2.77 | -58.12 | 3.3 |
| 5y average | 103.83 | -52.01 | -16.47 | -84.48 | 3.3 |
| Weighted average score | 6.7 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $747.9M significantly exceed its total debt $78.0M, ensuring strong financial flexibility
Total current assets $812.8M exceed Total current liabilities $147.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$47.3M limits the company's ability to reinvest or pay down debt